Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026
Image File
Original HTML

- Poster presentations feature preclinical in vitro and in vivo data of potentially first-in-class oral small molecule GIPR agonist ASC48 and next-generation once-monthly to once-quarterly GLP-1R/GIPR/GCGR triple peptide agonist ASC37

HONG KONG, Nov. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces two poster presentations of its obesity assets, oral small molecule GIPR agonist ASC48 and GLP-1R/GIPR/GCGR triple peptide agonist ASC37, at ObesityWeek® 2026 to be held November 14 to 17, 2026 in Washington, DC, the United States of America.

Presentation Details:

Abstract Title: Oral Small Molecule GIPR Agonist ASC48 for Obesity: In Vitro and In Vivo Studies

Session: Preclinical Models & Emerging Obesity Therapeutics

Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center

Presentation Time: November 14, 2026, 7:30 p.m.-8:30 p.m., EST

Abstract Title: ASC37 Showed 6-Fold Longer Half-Life Than Retatrutide in NHP and Marked Weight Loss in DIO Mice

Session: Preclinical Models & Emerging Obesity Therapeutics

Location: Exhibit Hall BCD, Gaylord National Resort & Convention Center

Presentation Time: November 14, 2026, 7:30 p.m.-8:30 p.m., EST

"We're excited to present the latest preclinical progress of our robust and highly differentiated obesity portfolio, including both small molecules and peptides, at ObesityWeek® 2026," said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, "These advancements reflect our strong determination to develop highly differentiated options to treat obesity."

About Ascletis Pharma Inc.

Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potentially best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides, such as its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes; ASC30_48FDC, a once-daily oral small molecule dual agonist, a fixed-dose combination of ASC30 (GLP-1R agonist) and ASC48 (GIPR agonist), ASC30_48_39FDC, a once-daily oral small molecule triple agonist, a fixed-dose combination of ASC30 (GLP-1R agonist), ASC48 (GIPR agonist) and ASC39 (amylin receptor agonist (SARA)), ASC39, an eloralintide-like potent selective amylin receptor agonist (SARA) once-daily oral small molecule, ASC30_39FDC, a once-daily oral small molecule dual agonist, a fixed-dose combination of ASC30 (GLP-1R agonist) and ASC39 (amylin receptor agonist (SARA)), ASC36i, an amylin receptor peptide agonist, designed for once-monthly to once-quarterly subcutaneous administration, ASC36_35i FDC, a triple peptide agonist, a fixed-dose combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), designed for once-monthly to once-quarterly subcutaneous administration, ASC35i, a GLP-1R/GIPR dual peptide agonist, designed for once-monthly to once-quarterly subcutaneous administration, ASC37i, a GLP-1R/GIPR/GCGR triple peptide agonist, designed for once-monthly to once-quarterly subcutaneous administration, ASC36_37i FDC, a quadruple peptide agonist, a fixed-dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), designed for once-monthly to once-quarterly subcutaneous administration, ASC36o, an amylin receptor peptide agonist, designed for once-weekly oral administration, ASC36_37o FDC, a quadruple peptide agonist, a fixed-dose combination of ASC36 (amylin receptor agonist) and ASC37 (GLP-1R/GIPR/GCGR agonist), designed for once-weekly oral administration, ASC36_35o FDC, a triple peptide agonist, a fixed-dose combination of ASC36 (amylin receptor agonist) and ASC35 (GLP-1R/GIPR agonist), designed for once-weekly oral administration, ASC37o, a GLP-1R/GIPR/GCGR triple peptide agonist, designed for once-weekly oral administration, ASC35o, a GLP-1R/GIPR dual peptide agonist, designed for once-weekly oral administration, for chronic weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).

For more information, please visit www.ascletis.com.

Contact:

Peter Vozzo

ICR Healthcare

443-231-0505 (U.S.)

[email protected]

Ascletis Pharma Inc. PR and IR Teams

+86-181-0650-9129 (China)

[email protected]

[email protected] 

SOURCE Ascletis Pharma Inc.

Share this article

Class (B2B/B2C)
B2B
Ingest Status
Need Review
Dedupe hash
prn_302925890
Press Eligible
Yes
Press Eligible Reason
QA FAIL (need review): Unsupported factual claim: the target says ASC37 is designed for once-monthly to once-quarterly administration, but the source specifies this design only for ASC37i, not for ASC37.
Source Name
Unknown Company
Original Summary

<p>- Poster presentations feature preclinical in vitro and in vivo data of potentially first-in-class oral small molecule GIPR agonist ASC48 and next-generation once-monthly to once-quarterly GLP-1R/GIPR/GCGR triple peptide agonist ASC37 HONG KONG, Nov. 2, 2026 /PRNewswire/ -- Ascletis...</p>

Original Link
Original Source
Image URL
https://mmx.prnewswire.com/media/MS1810014/Ascletis-Pharma-Logo.jpg?id=OA3049261&p=facebook
Generated Article_json
{"target_audience": "b2b", "is_medical": false, "ai_generated_title": "Ascletis to Show ASC37 6-Fold Half-Life Edge Over Retatrutide", "body_html": "<p><strong>HONG KONG – [CURRENT_DATE] --</strong> Ascletis Pharma Inc. (HKEX: 1672) will present preclinical data showing its triple peptide agonist ASC37 has a 6-fold longer half-life than retatrutide in non-human primates (NHP), alongside data on its oral GIPR agonist ASC48, at ObesityWeek 2026 in Washington, DC.</p><h5>Two posters scheduled for November 14 in Exhibit Hall BCD</h5><p>Both posters run in the \"Preclinical Models &amp; Emerging Obesity Therapeutics\" session on November 14, 2026, from 7:30 p.m. to 8:30 p.m. EST at the Gaylord National Resort &amp; Convention Center. ObesityWeek runs November 14 to 17, 2026.</p><h5>ASC37 posts marked weight loss in diet-induced obese mice</h5><p>The ASC37 abstract reports the 6-fold half-life advantage over retatrutide in NHP and marked weight loss in diet-induced obesity (DIO) mice. ASC37 is a GLP-1R/GIPR/GCGR triple peptide agonist designed for once-monthly to once-quarterly administration.</p><h5>ASC48 poster covers in vitro and in vivo studies of an oral GIPR agonist</h5><p>Ascletis describes ASC48 as a potentially first-in-class oral small molecule GIPR agonist for obesity. The poster presents both in vitro and in vivo data.</p><h5>Portfolio spans oral small molecules and long-acting peptides</h5><p>ASC48 also serves as a component of the company's fixed-dose combinations with its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist for chronic weight management and diabetes. Ascletis built its candidates in-house using its AI-assisted structure-based drug discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) and Peptide Oral Transport ENhancement Technology (POTENT).</p><p>Founder, Chairman and CEO Jinzi Jason Wu said the data reflect the company's determination to develop \"highly differentiated options to treat obesity.\"</p>", "meta_description": "Ascletis to present preclinical data on oral GIPR agonist ASC48 and triple agonist ASC37, with a 6-fold longer half-life than retatrutide in NHP, at ObesityWeek.", "seo_keywords": "Ascletis, ASC37, ASC48, ObesityWeek 2026, GIPR agonist, retatrutide, triple agonist, obesity, preclinical data, HKEX 1672", "companies": ["Ascletis Pharma Inc."], "industries": ["Biopharmaceuticals"], "markets_regions": ["United States", "China"], "news_type": ["event_participation", "research_data"], "products": ["ASC37"], "themes": ["obesity_therapeutics", "preclinical_research", "drug_development"], "events": ["ObesityWeek 2026"], "cta_text": "Learn more about Ascletis' obesity pipeline and ObesityWeek 2026 poster presentations", "learn_more": "https://www.ascletis.com", "fact_check": {"accuracy_score": 100, "legal_risk": "low", "corrections_made": [], "recommendation": "publish"}}
Content Hash (SHA-256, erste 32 hex)
16eb62a148ff940419d0833701fa48d4
Company Website
Company Website